original articlesthoracic tumorsSystematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
thoracic tumors
Under an Elsevier user license
open archive
Key words
exposure–response
immunotherapy
non-small-cell lung cancer
pembrolizumab
PD-L1
tumor size modeling
Cited by (0)
- †
Contributed equally to the development of the manuscript.
Copyright © 2016 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.